摘要
目的探讨淫羊藿苷(Icariin,Ica)对CT26小鼠结肠癌肝转移瘤生长的抑制及其机制。方法建立结肠癌肝转移小鼠模型,随机分为模型组,Ica高、中、低剂量组和希罗达组,每组7只,ig给药,3周后比较小鼠体重、肝重、瘤重及肺和腹膜转移情况。HE染色法分析Ica处理后各组转移瘤组织中的细胞生长情况,免疫组化SP法检测肿瘤组织中p53、Bax、Bcl-2的表达。结果Ica能够抑制结肠癌肝转移瘤鼠的肿瘤生长;HE染色结果显示Ica处理后的肿瘤细胞凋亡明显增多,且呈剂量依赖性。免疫组化结果表明,Ica作用后的转移瘤组织中p53和Bax蛋白上调,Bcl-2蛋白下调,且呈剂量依赖性。结论Ica可显著抑制小鼠CT26细胞结肠癌肝转移瘤的生长,其机制可能与上调p53和Bax蛋白,下调Bcl-2蛋白有关。
Objective To investigate the inhibitory effect of icariin(Ica) on the growth of colorectal cancer with liver metastasis of CT26 cell in mice and its mechanism. Methods A mouse model of colorectal cancer with liver metastasis was established and randomly divided into model group, Ica high, medium and low dose group and Xeloda group. Seven mice in each group, and administered with ig. The body weight, liver weight, tumor weight, and lung and peritoneal metastasis were compared after 3 weeks. Cells in each group of metastatic tumor tissue was analyzed by HE staining. The expression of p53, Bax and Bcl-2 protein in tumor tissues was detected by immunohistochemical staining. Results Ica could inhibit the tumor growth in colorectal cancer with liver metastasis. The results of HE staining showed that the apoptosis of tumor cells with Ica treatment was significantly increased in a dose-dependent manner. Immunohistochemistry showed that p53 and Bax proteins were up-regulated and Bcl-2 protein was down-regulated in the metastatic tumor tissues after Ica treatment in a dose-dependent manner. Conclusion Ica can significantly inhibit the growth of colorectal cancer with liver metastasis in mouse, which may be related to the up-regulation of the expression of p53 and Bax and down-regulation of the expression of Bcl-2 protein.
作者
张蕾
乔大伟
毛海燕
李玉芳
董小耘
孔桂美
卜平
ZHANG Lei;QIAO Da-wei;MAO Hai-yan;Li Yu-fang;DONG Xiao-yun;KONG Gui-mei;BU Ping(Yangzhou University Medical College,Yangzhou 225001,China;Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases,Yangzhou University,Yangzhou 225001,China;Laboratory of Microbiology and Immunology of Yangzhou University,Yangzhou 225001,China)
出处
《时珍国医国药》
CAS
CSCD
北大核心
2019年第8期1829-1832,共4页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金(81272537
81673736)
